Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
Cassava Sciences (NASDAQ: SAVA) has appointed Dr. Angélique Bordey as Senior Vice President of Neuroscience to lead the company's research and development efforts. Dr. Bordey, who currently serves as Vice Chair of the Department of Neurosurgery at Yale School of Medicine, will maintain her academic position part-time while focusing on evaluating simufilam as a potential treatment for TSC-related epilepsy and other pipeline indications.
Dr. Bordey's research, published in prestigious journals, was fundamental to Cassava's recently granted patent for using simufilam to treat TSC-related epilepsy. The company has secured a license agreement with Yale University for this patent. Her expertise in neuroscience and leadership in the TSC community is expected to advance Cassava's preclinical program and facilitate study collaborations.
Cassava Sciences (NASDAQ: SAVA) ha nominato la Dott.ssa Angélique Bordey come Senior Vice President di Neuroscienze per guidare le attività di ricerca e sviluppo dell'azienda. La Dott.ssa Bordey, attualmente Vice Presidente del Dipartimento di Neurochirurgia presso la Yale School of Medicine, manterrà il suo ruolo accademico part-time concentrandosi sulla valutazione di simufilam come possibile trattamento per l'epilessia correlata alla TSC e altre indicazioni in pipeline.
Le ricerche della Dott.ssa Bordey, pubblicate su riviste prestigiose, sono state fondamentali per il recente brevetto ottenuto da Cassava sull'uso di simufilam per trattare l'epilessia correlata alla TSC. L'azienda ha stipulato un accordo di licenza con la Yale University per questo brevetto. La sua esperienza nelle neuroscienze e il suo ruolo di leadership nella comunità TSC sono destinati a far progredire il programma preclinico di Cassava e a facilitare collaborazioni di studio.
Cassava Sciences (NASDAQ: SAVA) ha nombrado a la Dra. Angélique Bordey como Vicepresidenta Senior de Neurociencia para liderar los esfuerzos de investigación y desarrollo de la empresa. La Dra. Bordey, quien actualmente es Vicepresidenta del Departamento de Neurocirugía en la Yale School of Medicine, mantendrá su puesto académico a tiempo parcial mientras se enfoca en evaluar simufilam como un posible tratamiento para la epilepsia relacionada con TSC y otras indicaciones en desarrollo.
La investigación de la Dra. Bordey, publicada en revistas prestigiosas, fue fundamental para la reciente concesión de la patente de Cassava para el uso de simufilam en el tratamiento de la epilepsia relacionada con TSC. La empresa ha asegurado un acuerdo de licencia con la Universidad de Yale para esta patente. Su experiencia en neurociencia y liderazgo en la comunidad TSC se espera que impulsen el programa preclínico de Cassava y faciliten colaboraciones en estudios.
Cassava Sciences (NASDAQ: SAVA)는 회사의 연구 개발 노력을 이끌기 위해 앙겔리크 보르데이 박사를 신경과학 수석 부사장으로 임명했습니다. 현재 예일 의과대학 신경외과 부학장으로 재직 중인 보르데이 박사는 파트타임으로 학계 직위를 유지하면서 simufilam을 TSC 관련 간질 및 기타 파이프라인 적응증의 잠재적 치료제로 평가하는 데 집중할 예정입니다.
보르데이 박사의 연구는 권위 있는 학술지에 게재되었으며, 이는 Cassava가 최근 취득한 TSC 관련 간질 치료용 simufilam 특허에 핵심적인 역할을 했습니다. 회사는 이 특허에 대해 예일 대학교와 라이선스 계약을 체결했습니다. 그녀의 신경과학 전문 지식과 TSC 커뮤니티에서의 리더십은 Cassava의 전임상 프로그램을 발전시키고 연구 협력을 촉진할 것으로 기대됩니다.
Cassava Sciences (NASDAQ : SAVA) a nommé le Dr Angélique Bordey au poste de Vice-Présidente Senior des Neurosciences afin de diriger les efforts de recherche et développement de l'entreprise. Le Dr Bordey, qui est actuellement Vice-Présidente du département de neurochirurgie à la Yale School of Medicine, conservera son poste académique à temps partiel tout en se concentrant sur l'évaluation de simufilam comme traitement potentiel de l'épilepsie liée à la TSC et d'autres indications en développement.
Les recherches du Dr Bordey, publiées dans des revues prestigieuses, ont été essentielles pour le brevet récemment accordé à Cassava concernant l'utilisation de simufilam pour traiter l'épilepsie liée à la TSC. L'entreprise a conclu un accord de licence avec l'université de Yale pour ce brevet. Son expertise en neurosciences et son rôle de leader dans la communauté TSC devraient faire progresser le programme préclinique de Cassava et faciliter les collaborations d'études.
Cassava Sciences (NASDAQ: SAVA) hat Dr. Angélique Bordey zur Senior Vice President für Neurowissenschaften ernannt, um die Forschungs- und Entwicklungsaktivitäten des Unternehmens zu leiten. Dr. Bordey, die derzeit stellvertretende Vorsitzende der Neurochirurgie an der Yale School of Medicine ist, wird ihre akademische Position in Teilzeit beibehalten und sich darauf konzentrieren, simufilam als potenzielle Behandlung für TSC-bedingte Epilepsie und weitere Pipeline-Indikationen zu evaluieren.
Die Forschung von Dr. Bordey, veröffentlicht in renommierten Fachzeitschriften, war grundlegend für das kürzlich von Cassava erteilte Patent zur Verwendung von simufilam bei der Behandlung von TSC-bedingter Epilepsie. Das Unternehmen hat eine Lizenzvereinbarung mit der Yale University für dieses Patent abgeschlossen. Ihre Expertise in den Neurowissenschaften und ihre Führungsrolle in der TSC-Community sollen Cassavas präklinisches Programm vorantreiben und Studienkooperationen erleichtern.
- Appointment of highly qualified expert Dr. Bordey with relevant research experience in TSC-related epilepsy
- Recently granted patent for simufilam in TSC-related epilepsy treatment
- Secured license agreement with Yale University for the patent
- Potential expansion into additional pipeline indications
- Program still in preclinical stage, indicating long development timeline ahead
- Dr. Bordey will maintain dual roles, potentially limiting time commitment to Cassava
As SVP, Neuroscience, Dr. Bordey will lead Cassava’s ongoing research and development efforts
Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline indications
AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that Angélique Bordey, PhD, has joined the Company as Senior Vice President (SVP), Neuroscience, while continuing her tenured academic position at Yale School of Medicine on a part time basis.
Dr. Bordey will be primarily responsible for leading Cassava’s research and development efforts. Her scientific expertise will guide the Company’s preclinical program to evaluate simufilam as a potential treatment for TSC-related epilepsy, and potentially for additional pipeline indications. Dr. Bordey currently serves as the Vice Chair of the Department of Neurosurgery at Yale School of Medicine, where she holds the Rothberg Endowed Chair. She will limit the time devoted to those duties to allow her to perform her new role with Cassava.
“We are thrilled to have Dr. Angélique Bordey join us. Dr. Bordey will be a tremendous boost to Cassava’s efforts to transform the treatment paradigm for TSC-related epilepsy. Her research, published in Neuron and Science Translational Medicine, was the cornerstone of the recently granted patent that includes the use of simufilam to treat TSC-related epilepsy. Cassava’s subsequent license agreement with Yale University for that patent opens the door to explore this potential indication for simufilam. We believe that Dr. Bordey’s unique neuroscience expertise can be instrumental to advancing our preclinical program and that her stature as a leader in the TSC community may allow for productive study collaborations,” said Rick Barry, President and Chief Executive Officer of Cassava.
“Through my academic research and collaboration with the TSC Alliance, I have learned that TSC-related epilepsy is among the more challenging epilepsy syndromes to manage, often requiring innovative and individualized treatment approaches. It is exciting to work directly with the Cassava team to advance the evaluation of simufilam as a potential novel treatment for this devasting rare disease. I am hopeful that simufilam’s unique mechanism of action will provide a new approach to treating TSC-related epilepsy,” said Dr. Angélique Bordey, SVP, Neuroscience of Cassava.
About Angélique Bordey, PhD
Dr. Bordey is a highly respected, widely published neuroscientist and tenured professor who has dedicated her career to understanding neuronal signaling and unlocking the neurobiology of diseases such as tuberous sclerosis complex. She has been a member of the Departments of Neurosurgery and Cellular and Molecular Physiology at Yale School of Medicine for more than two decades. In her role as Vice Chair, Department of Neurosurgery at Yale School of Medicine, Dr. Bordey holds the Rothberg Endowed Chair. Over the course of Dr. Bordey’s academic career, her work has resulted in more than 125 publications, significant grant support and numerous invited lectures. Dr. Bordey has mentored and supervised numerous students and postdoctoral associates, overseen numerous grants and provided consulting advice to several biopharmaceutical companies.
Dr. Bordey earned her PhD in Neuroscience at University Louis Pasteur, Strasbourg, France and completed her post-doctoral fellowship at the University of Alabama at Birmingham. Prior to that, she earned Master’s Degrees from the University Louis Pasteur in Neurophysiology and the Ecole Polytechnique de Lyon in Chemistry. Dr. Bordey completed her Bachelor’s Degree in Mathematics, Physics, and Chemistry at Blaise Pascal College and her Baccalaureate at Lycée Saint Joseph, Montlucon, France.
About Cassava Sciences, Inc.
Cassava Sciences, Inc. (NASDAQ: SAVA), is a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders such as tuberous sclerosis complex (TSC)-related epilepsy, and potentially for additional pipeline indications. Simufilam is a proprietary, investigational oral small molecule that targets the filamin A protein. The Company is based in Austin, Texas.
For more information, please visit: https://www.CassavaSciences.com
For More Information Contact:
Investors
Sandya von der Weid
svonderweid@lifesciadvisors.com
Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
ESchoen@CassavaSciences.com
IR@cassavasciences.com
Cautionary Note Regarding Forward-Looking Statements:
This news release contains forward-looking statements that include but are not limited to statements regarding: our plans to conduct preclinical studies of simufilam relating to seizures in TSC, the potential for simufilam as a treatment for TSC-related epilepsy and other indications, the timing of anticipated milestones, and management appointments and comments made by our employees. These statements may be identified by words such as “anticipate”, “before,” “believe”, “could”, “expect”, “forecast”, “intend”, “may”, “pending,” “plan”, “possible”, “potential”, “prepares for,” “will”, and other words and terms of similar meaning.
Such statements are based on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to efficiently discontinue the Company’s Alzheimer’s disease development program, the ability to advance preclinical studies related to TSC-related epilepsy, and other risks inherent in drug discovery and development or specific to Cassava Sciences, Inc., as described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and future reports to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this news release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC’s website at www.sec.gov.
All of our pharmaceutical assets under development are investigational product candidates. They have not been approved for use in any medical indication by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes, if any, have not been established in any patient population. Consequently, none of our product candidates is approved or available for sale anywhere in the world.
Our clinical results from earlier-stage clinical trials may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.
We are in the business of new drug discovery, development and commercialization. Our research and development activities are long, complex, costly and involve a high degree of risk. Holders of our common stock should carefully read our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q in their entirety, including the risk factors therein. Because risk is fundamental to the process of drug discovery, development and commercialization, you are cautioned to not invest in our publicly traded securities unless you are prepared to sustain a total loss of the money you have invested.
FAQ
Who is Dr. Angélique Bordey and what is her new role at Cassava Sciences (SAVA)?
What is the significance of Cassava Sciences' (SAVA) recent patent for simufilam?
What is TSC-related epilepsy and why is Cassava Sciences (SAVA) targeting it?
How will Dr. Bordey's appointment impact Cassava Sciences' (SAVA) development pipeline?
